Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In other recent news, Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, delivering results that surpassed expectations. The company posted an earnings per share (EPS) of -$0.21, ...

Java has endured radical transformations in the technology landscape and many threats to its prominence. What makes this technology so great, and what does the future hold for Java? In a world ...

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...

Generic formats like JSON or XML are easier to version than forms. However, they were not originally intended to be ...

Nvidia's recent $700 million acquisition of Run:ai enhances GPU access and infrastructure flexibility. The acquisition of OctoAI for $250 million bolsters Nvidia's generative AI tools portfolio.

Chicago is an expansive city with dozens of neighborhoods, all known for their quirks, watering holes, landmarks and events. Downtown Chicago is no different. Chicago’s bustling downtown boasts many ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...